Premium
Pharmacokinetics of Hydroxyurea in Plasma and Cerebrospinal Fluid of HIV‐1‐Infected Patients
Author(s) -
Gwilt Peter R.,
Manouilov Konstantine K.,
McNabb JoCarol,
Swindells Susan S.
Publication year - 2003
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1177/0091270003256144
Subject(s) - pharmacokinetics , cerebrospinal fluid , pharmacology , nucleoside , drug , medicine , in vivo , oral administration , nucleoside analogue , hydroxycarbamide , blood–brain barrier , central nervous system , chemotherapy , chemistry , biology , microbiology and biotechnology , stereochemistry
Hydroxyurea has been shown to potentiate the activity of the antiretroviral nucleoside analogs. A significant complication of AIDS is invasion of the virus into the CNS, resulting in HIV‐associated dementia (HAD). Because of the polar nature of these nucleosides and the presence of efflux pumps in the blood‐brain barrier, only low CNS drug concentrations are achieved. Introduction of hydroxyurea into the CNS may therefore increase the antiviral activity of these drugs. This study evaluates the accessibility of hydroxyurea to the CNS following oral drug administration. Twelve HIV patients received 800 mg, 1000 mg, or 1200 mg oral hydroxyurea. Cerebrospinal fluid (CSF) and plasma drug concentrations were measured over 8 hours and simultaneously fitted to a pharmacokinetic model. It was determined that CSF hydroxyurea concentrations, corresponding to those found to increase antiretroviral nucleoside activity in vitro, were achieved.